Cipher Pharmaceuticals Stock Today
| CPH Stock | CAD 14.99 0.24 1.63% |
Performance0 of 100
| Odds Of DistressLess than 1
|
Cipher Pharmaceuticals is selling at 14.99 as of the 29th of November 2024; that is 1.63 percent increase since the beginning of the trading day. The stock's open price was 14.75. Cipher Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Cipher Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of August 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company was founded in 2000 and is headquartered in Oakville, Canada. CIPHER PHARMACEUTICALS operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on Toronto Stock Exchange. The company has 25.59 M outstanding shares of which 127.32 K shares are currently shorted by private and institutional investors with about 2.17 days to cover all short positions. More on Cipher Pharmaceuticals
Moving against Cipher Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cipher Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cipher Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cipher Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Interim Chairman | Craig Mull | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) | ||||
Cipher Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cipher Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsCipher Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cipher Pharmaceuticals' financial leverage. It provides some insight into what part of Cipher Pharmaceuticals' total assets is financed by creditors.
| |||||
Cipher Pharmaceuticals (CPH) is traded on Toronto Exchange in Canada and employs 7 people. Cipher Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 383.59 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cipher Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Cipher Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cipher Pharmaceuticals operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 25.59 M outstanding shares of which 127.32 K shares are currently shorted by private and institutional investors with about 2.17 days to cover all short positions.
Cipher Pharmaceuticals has accumulated about 9.25 M in cash with 16 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34.
Check Cipher Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCipher Pharmaceuticals holds a total of 25.59 Million outstanding shares. Cipher Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cipher Ownership Details
Cipher Pharmaceuticals Risk Profiles
Although Cipher Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Cipher Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.85 | |||
| Standard Deviation | 3.98 | |||
| Variance | 15.88 | |||
| Risk Adjusted Performance | (0.02) |
Cipher Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cipher Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Cipher Pharmaceuticals Corporate Management
Elected by the shareholders, the Cipher Pharmaceuticals' board of directors comprises two types of representatives: Cipher Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cipher. The board's role is to monitor Cipher Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cipher Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cipher Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hamed Ghanei | Chief Officer | Profile | |
| Bryan Jacobs | Chief Officer | Profile | |
| Diane Gajewczyk | Vice Affairs | Profile | |
| Chuoru Li | Co Controller | Profile | |
| David Miller | Director Fin | Profile |
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.